PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene’s projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. Our collaborators apply our technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity.
Three unique aspects of PamGene’s proprietary biomarker technology are:
The empowerment of a completely new way of translational biomarker development.
PamGene’s technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing.
The emphasis on evidence-based medicine development by delivering and supporting scientific hypotheses: Understanding the on and off-target activities of a medicine is key.
PamGene’s multi-marker tests enable the read-out of large sets of protein activities from cell based systems (enzymatic and binding activities).
Fully developed CE marked instrumentation for testing in the clinic is available. Testing in a CLIA certified laboratory can be organized.
Although PamGene’s approach is novel, the instrumentation, test kit production and testing procedures are well established.
